Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication (INVOLVE)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00577265
First received: December 18, 2007
Last updated: January 27, 2011
Last verified: January 2011
  Purpose

An observational study to investigate how patients experience the ability to adjust their asthma maintenance medication according to instructions received from their physician. The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.


Condition
Asthma

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication According to Instructions Received From Their Physician (AMD).

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.

Secondary Outcome Measures:
  • The secondary goal is to investigate the efficacy of the treatment with budesonide/formoterol AMD on the patients asthma control measured with the ACQ.

Study Start Date: November 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients

Criteria

Inclusion Criteria:

  • Inclusion Criteria: patients with prescription of budesonide/formoterol Turbuhaler 200/6 (adjustable maintenance dosing) and whom received instructions from their physician to adjust their asthma maintenance medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00577265

Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Hannie de Munnik AstraZeneca
Study Chair: Monique Scholtes AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00577265     History of Changes
Other Study ID Numbers: S43
Study First Received: December 18, 2007
Last Updated: January 27, 2011
Health Authority: Not required:

Keywords provided by AstraZeneca:
Asthma Control

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 23, 2014